Clinical Trial Update: A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD) [Phase 3]

View source ↗

Summary

A 52-week open-label safety study of PD 0332334 in subjects with Generalized Anxiety Disorder was terminated, according to the clinical trial update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• PD 0332334

Snippet

Sponsor: Pfizer | Conditions: Generalized Anxiety Disorder | Phase 3 | Status: TERMINATED